A Phase II Study of BAY 43-9006 (NSC 724772) in Patients With Malignant Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Feb 2011 Planned end date (Jan 2014) added as reported by ClinicalTrials.gov.
- 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.